Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolios

Glaxo-Innoviva's Triple Combo Inhaler Positive In Phase III

Published 09/20/2017, 09:44 PM
Updated 07/09/2023, 06:31 AM
ACAD
-
INVA
-
GSK
-
KDNY
-

GlaxoSmithKline plc (NYSE:GSK) and partner Innoviva, Inc. (NASDAQ:INVA) announced that its once-daily single inhaler triple therapy — Trelegy Ellipta (FF/UMEC/VI, fluticasone furoate/umeclidinium/vilanterol) — met primary endpoint in a phase III IMPACT study, showing reduction in exacerbations in patients with chronic obstructive pulmonary disease (COPD).

While fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium is a long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2-adrenergic agonist (LABA). This combination medicine will be delivered once daily in the Ellipta dry powder inhaler. Typically, the ICS/LAMA/LABA amalgamation for advanced COPD is delivered via two or more inhalers with a potentially differing dose regime. However, GlaxoSmithKline’s triple therapy combination offers a daily treatment in a single Ellipta inhaler.

Notably, this week, the triple combination therapy was approved in the United States under the brand name, Trelegy Ellipta, as maintenance therapy for treatment of patients with COPD. Last week, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion, recommending approval of this combination therapy in the EU.

Notably, the closed triple combination therapy is not licensed as a single inhaler triple therapy anywhere outside the United States.

GlaxoSmithKline’s shares are up 4.3% so far this year, comparing unfavorably with the 16.8% rally of the industry during the period.

The IMPACT study was a randomised, double-blind, 3-arm parallel group, multicentre program, conducted on a total of 10,355 patients. The trial evaluated Trelegy Ellipta in comparison to the dual therapies of Anoro Ellipta (UMEC/VI) and Relvar/Breo Ellipta (FF/VI).

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Data from the study demonstrated statistically significant reductions in the annual rate of on-treatment moderate/severe exacerbations in patients with COPD, which determines the primary endpoint of the study. The study met its secondary endpoints too. Based on the positive data from the IMPACT analysis, the company expects to commence global regulatory filing in the second quarter of 2018 for the given indication.

It is important to note that the combination therapy is also under assessment across countries including Australia and Canada.

Per the company’s press release, COPD is a progressive serious lung disease, commonly found to affect approximately 384 million people worldwide, thus representing a significant need for such therapies.

Zacks Rank & Stocks to Consider

GlaxoSmithKline currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. (NASDAQ:ADRO) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Aduro Biotech’s loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.41 to $1.24 for 2018 over the last 60 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.

ACADIA’s loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>



GlaxoSmithKline PLC (GSK): Free Stock Analysis Report

Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report

ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report

Innoviva, Inc. (INVA): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.